UA30251A - The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia - Google Patents

The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia

Info

Publication number
UA30251A
UA30251A UA98020639A UA98020639A UA30251A UA 30251 A UA30251 A UA 30251A UA 98020639 A UA98020639 A UA 98020639A UA 98020639 A UA98020639 A UA 98020639A UA 30251 A UA30251 A UA 30251A
Authority
UA
Ukraine
Prior art keywords
hypersympathicotonia
hypertonia
patients
treatment
along
Prior art date
Application number
UA98020639A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Катерина Миколаївна Амосова
Екатерина Николаевна Амосова
Дмитро Юрійович Скороходов
Дмитрий Юрьевич Скороходов
Олег Ігорович Лиховський
Олег Игоревич Лиховский
Артур Ротмирович Сапожников
Original Assignee
Національний Медичний Університет Ім.О.О.Богомольця
Национальный Медицинский Университет Им. А.А. Богомольца
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Національний Медичний Університет Ім.О.О.Богомольця, Национальный Медицинский Университет Им. А.А. Богомольца filed Critical Національний Медичний Університет Ім.О.О.Богомольця
Priority to UA98020639A priority Critical patent/UA30251A/en
Publication of UA30251A publication Critical patent/UA30251A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the medicine. The treatment includes the drug administration. The patient is given prazosin 2 mg divided into 4 doses of 0.5 mg each dose for 5 days.
UA98020639A 1998-02-05 1998-02-05 The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia UA30251A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UA98020639A UA30251A (en) 1998-02-05 1998-02-05 The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UA98020639A UA30251A (en) 1998-02-05 1998-02-05 The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia

Publications (1)

Publication Number Publication Date
UA30251A true UA30251A (en) 2000-11-15

Family

ID=74195488

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98020639A UA30251A (en) 1998-02-05 1998-02-05 The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia

Country Status (1)

Country Link
UA (1) UA30251A (en)

Similar Documents

Publication Publication Date Title
UA32636C2 (en) Method for reducing cholesterol content in human blood serum
MX9700081A (en) Tacrine pharmaceutical compositions.
NO20101190L (en) Use of buprenorphine in the manufacture of a medicament
ATE515265T1 (en) VITAMIN D AND ITS ANALOGUES FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISEASES
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
ZA924772B (en) Delayed therapy
PT946151E (en) DOSAGE FORM OF GROWING DOSE
MXPA05012810A (en) Memantine oral dosage forms.
ATE94393T1 (en) DOSE FORM FOR ORAL ADMINISTRATION OF HYPOGLYCAEMIC GLIPICIDE.
IL113651A0 (en) Pharmaceutical compositions containing alendronate and their use
EP0777484A4 (en) Intravenous alendronate formulations
ATE234602T1 (en) ADMINISTRATION FORM FOR THE DELIVERY OF INCREASING DOSES OF ACTIVE INGREDIENTS
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
RU95101385A (en) Products containing g-csf and tnf-binding protein
HUP9701777A2 (en) Use of raloxifene for producing pharmaceutical compositions for preventing breast cancer
BR0009380A (en) Improved cancer treatment with temozozomide
DE60222383D1 (en) MEDICAMENT FOR THE ADMINISTRATION OF AMIFOSTIN AND RELATED ACTIVE SUBSTANCES
MD1875G2 (en) Method of treatment of the acute viral hepatitis B
CA2435921A1 (en) Method of cancer therapy
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
UA30251A (en) The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
AR109456A2 (en) USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
DE60120371D1 (en) USING GROWTH HORMONE IN LESS BOXES